How have OPHLF shares performed in 2024?

Ono Pharmaceutical's stock was trading at $17.6850 at the beginning of 2024. Since then, OPHLF stock has decreased by 9.8% and is now trading at $15.96. View the best growth stocks for 2024 here .

How were Ono Pharmaceutical's earnings last quarter?

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) released its quarterly earnings results on Wednesday, January, 31st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.45 by $0.06. The business had revenue of $888.42 million for the quarter. Ono Pharmaceutical had a trailing twelve-month return on equity of 16.32% and a net margin of 25.43%.

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:OPHLF

Ono Pharmaceutical (OPHLF) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free OPHLF Stock Alerts

$15.96

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $15.96
▼
$15.96
50-Day Range: $15.96
▼
$17.69
52-Week Range: $15.96
▼
$20.63

Volume: 1,860 shs
Average Volume: 3,057 shs
Market Capitalization: N/A

P/E Ratio: 8.63
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get Ono Pharmaceutical alerts:

Ad InvestorPlace

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Ono Pharmaceutical Stock (OTCMKTS:OPHLF)

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

OPHLF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OPHLF Stock News Headlines

April 9, 2024 | finance.yahoo.com

Q4 2023 Cue Biopharma Inc Earnings Call

March 20, 2024 | uk.investing.com

Ono Pharmaceutical Co Ltd (OPHLY)

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 14, 2024 | msn.com

Don Lemon Says His Talk Show Deal with X Was Canceled After Tense Interview with Elon Musk: 'He's Mad at Me'

February 24, 2024 | msn.com

Ono Pharmaceutical Co., - Depositary Receipt () (OPHLY) Price Target Increased by 19.99% to 7.80

February 22, 2024 | finance.yahoo.com

Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets

February 20, 2024 | msn.com

London exhibition celebrates 'unknown artist' Yoko Ono

February 14, 2024 | uk.finance.yahoo.com

Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 14, 2024 | globenewswire.com

Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer

February 5, 2024 | msn.com

NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?

February 5, 2024 | investing.com

Ono Pharmaceutical Ltd (4528)

January 16, 2024 | seekingalpha.com

ODP: A Value Play With Catalysts

January 16, 2024 | wsj.com

Snack Maker Orion Slumps After Pharma Acquisition Push

December 21, 2023 | tmcnet.com

Ono Enters into Research Collaboration with UK Dementia Research Institute

December 19, 2023 | markets.businessinsider.com

BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research

December 16, 2023 | msn.com

Ono Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Increased by 29.83% to 7.51

December 9, 2023 | seekingalpha.com

ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting

December 1, 2023 | finance.yahoo.com

Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million

November 28, 2023 | finance.yahoo.com

U.S. Stocks Open Mostly Lower, With S&P 500 Falling Slightly Ahead Of Fed Speakers

November 28, 2023 | finance.yahoo.com

Nikkei Edges Lower on Yen Strength, Likely Position Adjustment

November 27, 2023 | finance.yahoo.com

Nikkei Falls 0.4% Amid JPY Strength

November 1, 2023 | msn.com

Ozempic, Wegovy demand drives up illegal sales of weight-loss drugs

October 28, 2023 | morningstar.com

Ono Pharmaceutical Co Ltd

September 1, 2023 | finance.yahoo.com

Ono Pharmaceutical Co. (OPHLF) Upgraded to Buy: Here's Why

July 30, 2023 | markets.businessinsider.com

ONO PHARMACEUTICAL is about to announce earnings — here's what Wall Street expects

January 27, 2023 | msn.com

USFDA gives exception to Glenmark Pharma to supply pneumonia drug from Baddi facility

See More Headlines

Receive OPHLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 1/31/2024
Today: 4/19/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:OPHLF
CUSIP: N/A
CIK: 940821
Web: www.ono.co.jp
Phone: (166) 263-5670
Fax: 816-6263-2950
Employees: 3,761
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $1.85
Trailing P/E Ratio: 8.63
Forward P/E Ratio: 8.49
P/E Growth: N/A
Net Income: $834.15 million
Net Margins: 25.43%
Pretax Margin: N/A
Return on Equity: 16.32%
Return on Assets: 14.16%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.52
Quick Ratio: 3.04

Sales & Book Value

Annual Sales: $3.31 billion
Price / Sales: N/A
Cash Flow: $1.87 per share
Price / Cash Flow: 8.52
Book Value: $10.76 per share
Price / Book: 1.48

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.63

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Gyo Sagara (Age 66)
CEO, President & Representative Director
Comp: $905.16k
Mr. Masaki Ito
Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. Tax
Takehiro Yamada
Corporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion Office
Masayuki Tanigawa
Corporate Officer & Executive Director of Corporate Development & Strategy
Mr. Toichi Takino Ph.D. (Age 56)
Senior Managing Executive Officer, Head of Research Division & Director
Mr. Toshihiro Tsujinaka (Age 60)
Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director
Hiromu Habashita Ph.D.
Corporate Officer, Dep. Executive Dir. of Discovery & Research and Research Center of Immunology
Kiyoaki Idemitsu (Age 60)
Managing Executive Officer, GM of Development Division & Director
Shinji Takai M.D.
Ph.D., Corporate Officer & Head of Medical Affairs
Satoshi Takahagi
Corporate Officer and Executive Director of Sales, Marketing & Primary Care Business Division

Key Competitors

View All Competitors

OPHLF Stock Analysis - Frequently Asked Questions

How have OPHLF shares performed in 2024?: Ono Pharmaceutical's stock was trading at $17.6850 at the beginning of 2024. Since then, OPHLF stock has decreased by 9.8% and is now trading at $15.96.
View the best growth stocks for 2024 here.
How were Ono Pharmaceutical's earnings last quarter?: Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF) released its quarterly earnings results on Wednesday, January, 31st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.45 by $0.06. The business had revenue of $888.42 million for the quarter. Ono Pharmaceutical had a trailing twelve-month return on equity of 16.32% and a net margin of 25.43%.
How do I buy shares of Ono Pharmaceutical?: Shares of OPHLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:OPHLF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial